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The prevalence of diabetes mellitus is increasing world-1
wide paralleling the rise in obesity, sedentary lifestyle, and
increased life expectancy. It is estimated that globally 382
million people live with diabetes and the International
Diabetes Federation expects this number to rise to 592
million by 2035. Persons with diabetes are at increased risk2
of developing microvascular complications such as diabetic
retinopathy (DR), a leading cause of blindness, diabetic
nephropathy (DN), a leading cause of renal failure, and
diabetic peripheral neuropathy (DPN), a leading cause of
diabetic foot disorders and lower limb amputations, and all
are major causes of morbidity and deaths. As many older
persons with diabetes are living longer, the prevalence of
these microvascular complications is also on the rise despite
improvements in control of glycemia, blood pressure, and
lipid levels. Given that these microvascular complications
are largely preventable, it is important to identify novel
risk factors or biomarkers associated with early detection of
onset/progression of DR, DN, and DPN to mitigate against
these microvascular complications.
Several biomarkers associated with the pathogenic mech-
anisms that underlie these microvascular complications
including inflammation, endothelial dysfunction, oxida-
tive stress, hemostasis, microangiopathy, proteomic and
metabolomic markers, and those representing end-organ
damage have facilitated improved risk stratification besides
providing insight into the underlying etiology of the disease.
This special issue contains six papers which examine some of
the critical issues in the identification and understanding of
novel risk factors and their potential in the identification and
risk stratification of diabetic microvascular complications.
The paper by Q. Ma and colleagues entitled “Regular
Chinese Green Tea Consumption Is Protective for Diabetic
Retinopathy: A Clinic-Based Case-Control Study” examines
the association between regular Chinese green tea consump-
tion and the risk of DR in persons with diabetes from China.
Green tea is a popular beverage in East Asia and contains
huge amount of polyphenols with strong antioxidant activity
and anti-inflammatory properties with evidence in support
of clinical benefit across a range of chronic conditions. The
authors observed that regular consumption of Chinese green
tea for at least a year reduced the risk of DR by up to 50%
reduction compared to those who did not consume green
tea. The study findings if confirmed in prospective studies
with larger sample size suggest regular Chinese green tea
consumptionmay offer a cheap and easy-to-operate approach
for preventing DR in low-income countries.
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J. Jin and colleagues present a paper in this special issue
entitled “Development of Diagnostic Biomarkers for Detect-
ing Diabetic Retinopathy at Early Stages Using Quantitative
Proteomics.” They performed a comprehensive proteomic
analysis of DR to identify novel biomarker candidates that
are specifically expressed within the human vitreous. This
was achieved through data-mining of previously published
DR-related studies as well as de novo analysis of novel
experimental data. The in silico analysis identified 96 plau-
sible candidates from previously published literature which
following de novo verification in plasma samples from per-
sons with diabetes identified 11 proteins showing significant
differences and a final 4-proteinmultimarker panel including
ITIH2, APOA4, C7, and CLU significantly improved the risk
prediction models between no DR and both proliferative and
nonproliferativeDR.The proposed systematic bioinformatics
and de novo proteomic analysis pipeline has identified novel
biomarkers associated with DR with strong discriminatory
power offering future potential for clinical utility.
The paper by C. W. Wong and colleagues entitled
“Serum Cystatin C, Markers of Chronic Kidney Disease,
and Retinopathy in Persons with Diabetes” examines the
potential for cystatin C to predict DR outcomes better than
renal function measures derived from serum creatinine and
albuminuria. Chronic kidney disease (CKD) defined by the
three markers of serum creatinine, serum cystatin C, and
albuminuria has been shown to improve prediction of renal
failure and mortality. The aim of this study was to determine
if CKD defined by all three markers (creatinine, albuminuria,
and cystatin C) was more strongly indicative of moderate DR
than each marker in isolation or in dual combination. The
study concluded that CKD defined by a triple marker panel
was strongly associated with moderate DR in Indian adults
with diabetes. If confirmed by future prospective studies and
in other populations, a triple marker approach may have
implications on changing clinical practice to incorporate
cystatin C to improve risk stratification of DR in persons with
CKD. This group of high-risk individuals may benefit from
closer surveillance and more timely intervention before the
onset of irreversible sight threatening complications.
E. M. Lipner and colleagues present a paper entitled
“Linkage Analysis of Genomic Regions Contributing to the
Expression of Type 1 Diabetes Microvascular Complications
and Interaction with HLA.” Evidence for familial inheritance
in diabetic complications has been clearly demonstrated, sug-
gesting a genetic contribution to these phenotypes. Although
many linkage and association studies have focused on iden-
tifying T1D susceptibility loci, elucidation of the underlying
genetic architecture of diabetic complications has proved
elusive. Few genetic linkage studies have focused beyond
renal complications of T1D and the study by E.M. Lipner and
colleagues is the first to use linkage analysis to investigate the
influence of the HLA region on the manifestation of diabetic
complications.Their study has used a largewell-characterized
cohort of T1D families to identify gene-loci that predispose
to T1D complications focusing specifically on a previously
identified region of chromosome 6. The “any complication”
phenotype identified three loci, including the HLA locus
and two novel complications-related loci on chromosome
6, providing strong support for inherited influences that
contribute to the manifestation of diabetic complications.
G. J. McKay and colleagues present a paper entitled
“Bioinformatic Evaluation of Transcriptional Regulation of
WNT Pathway Genes with Reference to Diabetic Nephropa-
thy.” Members of the WNT/𝛽-catenin pathways have been
previously implicated in the characteristic DN disease pro-
cesses of interstitial fibrosis and glomerular sclerosis. These
processes are partially controlled by transcription factors
(TFs), proteins that bind to gene promoter regions attenu-
ating their regulation. This paper sought to identify whether
predicted cis-acting transcription factor binding sites (TFBS)
are overrepresented within the promoter regions of WNT
pathway members compared to genes across the genome.
Three TFBS profiles were found to be significantly enriched
within the WNT pathway genes examined and their expres-
sion profiles significantly altered in publically available DN-
related datasets. This study highlights the effectiveness of
an in silico pipeline to identify key regulators of this path-
way. Modification of TF binding to gene promoter regions
implicated in DN pathology may reduce disease progression,
making refinement of targeted therapeutic strategies possible
through clearer delineation of their role.
The paper by J. McEneny and colleagues entitled
“A Cross-Sectional Study Demonstrating Increased Serum
Amyloid A Related Inflammation in High-Density Lipopro-
teins from Subjects with Type 1 Diabetes Mellitus and
How This Association Was Augmented by Poor Glycaemic
Control” examines whether HDL-related inflammation is
increased in subjects with type 1 diabetes mellitus (T1DM).
Inflammatory atherosclerosis is increased in subjects with
T1DM. Normally high-density lipoproteins (HDL) protect
against atherosclerosis; however, in the presence of serum
amyloid A (SAA) related inflammation, this property may
be reduced. SAA augments atherogenesis by enhancing the
binding of HDL to the arterial wall. Authors observed
increased SAA related inflammation in subjects with T1DM 3
that was augmented by poor glycemic control.The study find-
ings suggest that SAA is a useful inflammatory-biomarker in
T1DM, whichmay contribute to the accelerated atherosclero-
sis risk in these subjects.
In summary, the complexity of the task required to
better understand the pathogenic mechanisms associated
with diabetic complications looms largewithmany important
questions still remaining unanswered. We hope that the
papers presented in this special issue will help inform the
research agenda necessary for future progress in this field.
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